Randomized trial · people

Tirzepatide: better sleep and quality of life scores in SURMOUNT-OSA

Checked against the paper Randomized trialPublished by PepVault

The takeaway

Beyond fewer breathing pauses during sleep, people with sleep apnea on tirzepatide in this trial said they slept, functioned and felt better than those on placebo.

Kind
Randomized trial
Studied in
People
Published
2025
Journal
Sleep Med

What they tested

The team tested whether tirzepatide changed how people with obstructive sleep apnea and obesity rated their own sleep, daytime functioning, symptoms and quality of life.

How the study was done

Two randomized, placebo-controlled phase 3 trials gave people with moderate-to-severe obstructive sleep apnea and obesity tirzepatide (10 mg or 15 mg) or placebo, an inactive dummy treatment, for 52 weeks. In Study 2, people who used PAP, a breathing therapy for sleep apnea, stopped it before their sleep tests and questionnaires.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At 52 weeks, people on tirzepatide reported significantly better scores than placebo on questionnaires about sleep-related impairment, sleep disturbance, activity level and health-related quality of life, plus most areas of a general health survey. They also rated their overall symptom status and change as better than the placebo group did. Daytime sleepiness scores changed significantly in Study 1.

What it doesn’t show

These are self-reported questionnaire results over 52 weeks in people with moderate-to-severe sleep apnea and obesity, so they may not apply to milder sleep apnea or to people without obesity. The sleepiness result was significant in Study 1 only.

The paper

Kanu et al. Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity. Sleep Med. 2025.

The compound

More studies on Tirzepatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo